Financial Statements and Exhibits
Lists the financial statements, pro forma financial information, and exhibits filed or furnished with the 8-K. Always present when the 8-K attaches a press release, contract, or other exhibit — typically appearing alongside another substantive item.
Recent disclosures
-
BlueOne Technologies replaces auditor and completes name change
-
Table Trac presents slides at annual meeting; content not disclosed
-
Atmus declares $0.055 quarterly dividend payable June 10, 2026
-
Kentucky First Federal Bancorp Q3 net income $581K; nine-month net $1.2M, both up sharply
-
Auburn National declares $0.27 quarterly dividend, payable June 25
-
Ryvyl consummates merger with RTB Digital, changes name and ticker to RTB
-
First National presents at annual meeting; details unavailable (image exhibit only)
-
USA Rare Earth files audited SVRE financials, pro forma, and updates risk factors for pending merger
-
Ondas registers 2.77M shares for resale by Mistral acquisition stockholders
-
Neonode Q1 2026 revenue $0.6M (+19.7% YoY), loss from operations $1.9M
-
WM promotes Tara Hemmer to COO; Rafa Carrasco retiring in July
-
CIMG Q2 revenue $3.2M; 6-month revenue $18.9M (82,969% YoY); holds 730 BTC worth $49.85M
-
ACV Auctions enters $50M accelerated share repurchase with Citibank; initial ~70% delivery
-
Assertio to be acquired by Zydus for $23.50/share cash; terminates prior Garda deal
-
Knight-Swift declares $0.20 Q2 dividend, payable June 22, 2026; record date June 8
-
Beasley Q1 rev $42.6M (-12.9% YoY); net income $3.2M ($1.77/dil EPS) vs prior yr loss
-
May 13, 2026 12:57 UTC Cohen & Steers Income Opportunities REIT, Inc. other_material
Cohen & Steers Income Opportunities REIT acquires 268K sf shopping center near Charlotte via JV
-
Eightco reports ~$340M total holdings: $90M OpenAI, 283M WLD, 11K ETH, $129M cash
-
Silexion begins GMP manufacturing of SIL204 with Catalent; Phase 2/3 trial approved at Israeli site
-
SmartRent stockholders approve amended equity plan and elect directors
-
Lite Strategy reports $0.7M yield from LTC covered calls, repurchases 1.6M shares
-
Fate Therapeutics Q1 2026: $174.8M cash, $1.3M revenue; FT819 lupus trial on track
-
CDW authorizes $1B share repurchase increase, boosting total authorization to ~$1.5B
-
SS Innovations Q1 revenue $11.1M (+117% YoY); net loss narrows to $3.6M; installations up 73%
-
QT Imaging Q1 revenue $6.5M (+133% YoY); net loss $3.4M; reaffirms FY2026 guidance ~$39M
-
Navitas Semiconductor raises $122M net via ATM equity offering; program fully sold
-
Nauticus Robotics hires Brian Allen as CRO; also amends debt terms and issues convertible note
-
ARS Pharma appoints Donn Casale as President effective June 1, 2026
-
Astrotech Q3 FY2026: R&D expense down 28%; TRACER 1000 deployed in 37 sites across 16 countries
-
Wayfair proposes $400M secured notes due 2034; repurchases $46M of 2028 convertibles
-
Whitehawk Therapeutics raises $87.5M in PIPE, extends cash runway into H2 2028
-
Bloomia Q3 revenue up 16% to $14.4M but swings to $0.8M net loss; completes $12.1M rights offering
-
Spruce Biosciences Q1 net loss $12.3M; cash $54.1M (Mar 31), $107.3M (Apr 30)
-
Xenetic Biosciences Q1 2026 net loss down 49% to $0.5M; royalty revenue up 36% to $0.8M
-
Protara Therapeutics Reports Q1 2026 Results, Advances TARA-002 Programs in LMs and NMIBC
-
NOVAGOLD releases 2025 Sustainability Report covering ESG performance and Donlin Gold project
-
Moleculin reports preliminary blinded CR rate ~30% in MIRACLE trial; first unblinding before June 30
-
Leatt Corp. authorizes $419,410 share buyback, balance of previous $750K plan
-
Tyra Biosciences Q1 net loss $39.3M; cash $383.5M; SURF302 data August 2026
-
Future Vision II issues $191K promissory note to sponsor for one-month deadline extension
-
Local Bounti Q1 2026 revenue $13.3M (+15% YoY), net loss improves to $12.7M from $37.7M
-
Altimmune Q1 net loss $22.6M; cash $535M; PERFORMA Phase 3 MASH trial initiation in H2 2026
-
Rent the Runway CEO Jennifer Hyman resigns; Teri Bariquit appointed interim CEO effective May 15
-
Arbutus Q1 net income $169.7M ($0.88/share) on $179.1M revenue from Moderna settlement
-
Vishay Q1 revenues $839.2M, GAAP EPS $0.05; book-to-bill 1.34
-
Milestone Q1 2026 net loss $26.1M; CARDAMYST launch yields $0.2M revenue, 600 scripts
source · SEC Form 8-K instructions · see methodology